Organogenesis Holdings, Inc. (ORGO)

NASDAQ: ORGO · Delayed Price · USD
5.46
-0.46 (-7.77%)
At close: May 18, 2022 4:00 PM
5.49
0.03 (0.55%)
After-hours:May 18, 2022 5:05 PM EDT
Market Cap705.05M
Revenue (ttm)463.62M
Net Income (ttm)85.05M
Shares Out129.13M
EPS (ttm)0.71
PE Ratio7.69
Forward PE17.42
Dividendn/a
Ex-Dividend Daten/a
Volume1,235,718
Open5.66
Previous Close5.92
Day's Range5.38 - 5.78
52-Week Range5.30 - 19.75
Beta1.59
AnalystsBuy
Price Target19.64 (+259.7%)
Earnings DateMay 10, 2022

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that prod...

IndustryBiotechnology
Founded1985
Employees950
Stock ExchangeNASDAQ
Ticker SymbolORGO
Full Company Profile

Financial Performance

In 2021, ORGO's revenue was $468.06 million, an increase of 38.36% compared to the previous year's $338.30 million. Earnings were $94.90 million, an increase of 450.67%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price forecast is 19.64, which is an increase of 259.71% from the latest price.

Price Target
$19.64
(259.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Organogenesis (ORGO) Q1 Earnings Lag Estimates

Organogenesis (ORGO) delivered earnings and revenue surprises of -80% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results

CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of prod...

1 week ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Organogenesis Holdings Inc. for Potential Breaches of Fid...

NEW YORK , May 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim inv...

2 weeks ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Organogenesis Holdings Inc.

Wilmington, Delaware--(Newsfile Corp. - April 21, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Organogenesis Holdings Inc. (NASDAQ: ORGO) on behalf...

3 weeks ago - Newsfile Corp

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advan...

1 month ago - GlobeNewsWire

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

1 month ago - GlobeNewsWire

Is This Healthcare Stock a Value Trap?

Don't be blinded by its attractive valuation.

2 months ago - The Motley Fool

Organogenesis Named One of 50 Highest Growth Companies in Massachusetts by the Boston Business Journal

CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

2 months ago - GlobeNewsWire

Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference

CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

2 months ago - GlobeNewsWire

Why Organogenesis Holdings Stock Blasted 21% Higher Today

The company delivered quite an upside surprise with its fourth-quarter earnings release.

2 months ago - The Motley Fool

Organogenesis' Q4 Profit Jumps More than 150% To $54M, Issues Solid FY22 Guidance

Organogenesis Holdings Inc's (NASDAQ: ORGO) Q4 FY21 sales increased 20% Y/Y to $128.6 million, beating the consensus of $124.70 million. The increase in net revenue was driven by a 30% increase in Advan...

2 months ago - Benzinga

Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates

Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 202...

CANTON, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...

2 months ago - GlobeNewsWire

Organogenesis (ORGO) Stock Jumps 7.4%: Will It Continue to Soar?

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

3 months ago - Zacks Investment Research

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February

CANTON, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

3 months ago - GlobeNewsWire

Deadline Today Alert: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000...

Los Angeles, California--(Newsfile Corp. - February 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organogenesis Holdi...

3 months ago - Newsfile Corp

ORGO Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages Organogenesis Holdings Inc. Investors wi...

New York, New York--(Newsfile Corp. - February 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Organogenesis Holdings Inc. (NASDAQ: ORGO) betwe...

3 months ago - Newsfile Corp

ORGO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Organogenesis Holdings Inc. Investors of Class Action

New York, New York--(Newsfile Corp. - February 8, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Organogenesis Holdings Inc. ("Organogen...

3 months ago - Newsfile Corp

ORGO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 8, 2022 in the Class Action Filed on B...

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Organogenesis Holdings Inc. (NASDAQ: ORGO) alleging that the...

3 months ago - PRNewsWire

Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $1...

Los Angeles, California--(Newsfile Corp. - February 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organogenesis Holdi...

3 months ago - Newsfile Corp

ORGO Final Deadline Tomorrow: Rosen, Globally Respected Investor Counsel, Encourages Organogenesis Holdings Inc. Inve...

New York, New York--(Newsfile Corp. - February 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Organogenesis Holdings Inc. (NASDAQ: ORGO) betwe...

3 months ago - Newsfile Corp

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 1, 2022

CANTON, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pro...

3 months ago - GlobeNewsWire

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Organogenesis Investors of a Lead Plaintiff Deadline of Fe...

NEW YORK, Feb. 7, 2022 /PRNewswire/ -- Attention Organogenesis Holdings Inc. ("Organogenesis") (NASDAQ: ORGO) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has comme...

3 months ago - PRNewsWire

TUESDAY DEADLINE: Organogenesis Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action...

SAN DIEGO--(BUSINESS WIRE)-- #ORGOstock--The suit alleges defendants issued false statements re: Organogenesis business and prospects, resulting in its stock trading at inflated prices.

3 months ago - Business Wire

Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Organogenesis Holdings Inc. (ORGO) Investors of Filing...

RADNOR, Pa.--(BUSINESS WIRE)---- $ORGO--Kessler Topaz Meltzer & Check, LLP Reminds Organogenesis Holdings Inc. (ORGO) Investors of Filing Deadline in Class Action Lawsuit

3 months ago - Business Wire